地塞米松磷酸钠具有抗炎、抗过敏、抗风湿、免疫抑制作用，常用于过敏及自身免疫性疾病。贝壳财经 记者在国家药监局官网查询发现，目前，地塞米松磷酸钠原料药有多个批文，生产单位包括津药药业、 上海新华联制药有限公司、仙琚制药、西安国康瑞金制药、江苏联环药业等。 针对行政处罚对公司影响，津药药业在公告中表示，上述罚没款合计金额占公司2024年经审计的营收、 归母净利润的比例分别为2.15%和51.85%。 公司进一步表示，目前地塞米松磷酸钠原料药产品生产和销售情况正常。上述罚没款合计金额将相应减 少公司2025年归母净利润6919.23万元。 津药药业称，已责令相关部门第一时间组织整改，采取四方面整改措施。整改措施提及，已制定可落实 的销售方案，发布了降价通知，主动下调地塞米松磷酸钠原料药价格，确保药品供应。 根据津药药业发布的今年一季度报告，报告期内，公司营业收入约7.86亿元，同比减少9.03%；归母净 利润5805.01万元，同比增长0.07%。 随着多家上市公司披露《行政处罚决定书》，针对地塞米松磷酸钠原料药的垄断行为正在逐步浮出水 面。 4月30日，津药药业发布公告表示，因涉及达成并实施"固定或者变更商品价格 ...

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]

证券代码：600488 证券简称：津药药业 编号：2024-030 津药药业股份有限公司 关于子公司注射用甲泼尼龙琥珀酸钠 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天 津）制药有限公司（以下简称"津药和平"） 注射用甲泼尼龙琥珀酸钠（以 下简称"该药品"）获得多米尼加共和国卫生部注册证书（标志着可以生产 并在多米尼加共和国市场销售该产品），现将相关信息公告如下： 一、药品的基本情况 二、药品的其他相关情况 注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、 免疫抑制治疗、血液疾病和肿瘤的治疗、休克的治疗等。2023 年津药和平向 多米尼加共和国卫生部提出注册申请，2025 年 4 月收到卫生部通知，取得注 册证书。 注 射 用 甲 泼 尼 龙 琥 珀 酸 钠 原 研 厂 家 为 美 国 辉 瑞 ， 商 品 名 为 SOLU-MEDROL，最早于 1959 年在美国上市，随后陆续在欧洲、中国、日本 等主流国家上市并销售。根据 IQVIA 数据库显示，甲泼尼龙类注射剂 2023 年、2024 年全球市场销售额分别为 5.26 亿美元、5.21 亿美元。 三、对上市公司影响及风险 ...

证券代码：600488 证券简称：津药药业 编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司 2025 年 4 月 30 日，津药药业股份有限公司（以下简称"公司"）收到 天津市市场监督管理委员会下发的《行政处罚决定书》（津市监垄处〔2025〕 1 号），现将相关情况公告如下： 关于收到行政处罚决定书的公告 一、决定书主要内容 天津市市场监督管理委员会认为，公司与具有竞争关系的其他经营者， 就地塞米松磷酸钠原料药所实施的一系列行为，违反了《反垄断法》第十 七条第（一）项的规定，属于达成并实施"固定或者变更商品价格"垄断 协议的行为，应当依据《反垄断法》第五十六条的规定依法追究法律责任。 根据《反垄断法》第五十六条第一款、第五十九条，综合考虑公司违 法行为的性质、程度、持续时间、消除违法后果的情况、积极进行整改等 因素，天津市市场监督管理委员会责令公司停止违法行为，并作出行政处 罚如下：（一）没收违法所得 42,764,400.00 元；（二）并处 2023 年度销售 额 8%的 ...

Core Viewpoint - The company has reported its first-quarter financial results for 2025, highlighting significant developments in product approvals and strategic initiatives aimed at enhancing operational efficiency and shareholder returns [12][28]. Financial Data - The company achieved a revenue of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan in 2024 [12]. - The company plans to distribute a cash dividend of 0.98 yuan per 10 shares for the 2024 fiscal year, totaling approximately 107 million yuan, maintaining a cash dividend ratio of 80.18% [15]. Product Approvals and Market Expansion - The company received approval for the active pharmaceutical ingredient (API) Fumarate Formoterol and the inhalation solution from the National Medical Products Administration, which is expected to enhance its market presence [5]. - The company’s Dexamethasone Sodium Phosphate API has been approved for sale in Brazil, which will aid in expanding its international market footprint [5]. - The company obtained a production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities [5]. Research and Development - In 2024, the company invested 248 million yuan in R&D, representing 7.7% of its main business revenue, and achieved significant milestones in drug approvals [16]. - The company plans to focus on six key areas, including ophthalmology and dermatology, to enhance its product pipeline and market competitiveness [17]. Compliance and Governance - The company is committed to enhancing its compliance management systems and has implemented various measures to improve operational efficiency and risk management [18][22]. - The company has revised its governance documents to align with regulatory requirements and improve its response to public sentiment [22]. Investor Relations - The company emphasizes the importance of information disclosure and has actively engaged with investors through various channels, including regular reports and investor education initiatives [20][21]. - The company has received a B-level rating for information disclosure from the Shanghai Stock Exchange, reflecting its commitment to transparency [20].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于2025年4月28日召 开公司第九届董事会第十六次会议及第九届监事会第十二次会议，分 别审议通过了《关于计提减值准备的议案》。具体情况如下： 一、资产减值准备的计提概况 为了更加客观、公允地反映公司2025年3月31日的财务状况以及 2025年第一季度的经营成果，根据《企业会计准则》相关规定和公司 会计政策，基于谨慎性原则，公司对相关资产进行减值测试，本期计 提各项减值准备共计2,174.22万元，收回或转回328.40万元，转销 1,800.95万元。具体如下： 证券代码：600488 证券简称：津药药业 编号：2025-026 津药药业股份有限公司 关于计提减值准备的公告 单位：万元 | 序 号 | 类别 | 本期计提 | 本期收回/转回 | 本期转销 | | --- | --- | --- | --- | --- | | 1 | 应收账款坏账准备 | 26.86 | 0.00 | 0.00 | | 2 | 其他应收款坏账准备 ...

证券代码：600488 证券简称：津药药业 编号：2025-027 津药药业股份有限公司 第九届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届监事会第十二次会 议于 2025 年 4 月 28 日以通讯表决的方式召开。会议由监事会主席赵炜 先生主持，应参加表决监事 3 人，实际表决监事 3 人。会议符合《公司 法》和《公司章程》的有关规定。会议经过审议，与会监事全票通过如 下提案： 特此公告。 津药药业股份有限公司监事会 2025 年 4 月 28 日 1 / 1 1.审议通过公司《2025 年第一季度报告》 公 司 《 2025 年 第 一 季 度 报 告 》 详 见 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）同日披露的公告。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 2.审议通过关于计提减值准备的议案 计提减值准备事项的决策程序合法、依据充分，计提符合企业会计 准则等相关规定，公允地反映了公司的资产 ...

证券代码：600488 证券简称：津药药业 编号：2025-025 公司《2025年第一季度报告》详见上海证券交易所网站（www.sse.com.cn） 同日披露的公告。此议案在提交董事会审议前，已经公司董事会审计与风 险控制委员会审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2.审议通过关于计提减值准备的议案 公司依据实际情况计提减值准备，符合《企业会计准则》和公司财务 管理制度的相关规定，公允地反映了公司的资产状况，同意公司本次计提 减值准备方案。具体内容详见上海证券交易所网站（www.sse.com.cn）同日 披露的公告。 津药药业股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第十六次会议 于 2025 年 4 月 28 日以通讯方式召开。本次会议的通知已于 2025 年 4 月 18 日以电子邮件的方式送达公司各位董事、监事和高管人员。会议应参加表 决董事 9 人，实际表决董事 9 人。会议 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 785,765,994.13, a decrease of 9.03% compared to CNY 863,769,688.70 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,050,125.92, showing a slight increase of 0.07% from CNY 58,012,016.03 year-on-year[4] - Total operating revenue for Q1 2025 was ¥785,765,994.13, a decrease of 9.05% compared to ¥863,769,688.70 in Q4 2024[19] - Net profit for Q1 2025 increased to ¥75,460,172.70, compared to ¥72,482,506.08 in Q4 2024, representing a growth of 3.93%[19] - The company’s total comprehensive income for the period was 75,907,038.19 RMB, compared to 73,365,945.30 RMB in the previous period, reflecting a growth of approximately 2.1%[20] - Basic and diluted earnings per share remained stable at 0.053 RMB per share for both Q1 2025 and Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -10,502,031.63, a decline of 120.37% compared to CNY 51,548,996.07 in the previous year, primarily due to an increase in accounts receivable and a decrease in sales collections[5] - In Q1 2025, the company reported a net cash flow from operating activities of -10,502,031.63 RMB, a decrease from 51,548,996.07 RMB in Q1 2024[22] - The company incurred total operating cash outflows of 637,404,364.07 RMB in Q1 2025, compared to 782,620,253.43 RMB in Q1 2024[23] - The net cash flow from financing activities was 128,961,037.93 RMB in Q1 2025, a significant improvement from -37,859,927.73 RMB in Q1 2024[24] - The company reported a decrease in cash inflows from operating activities, totaling 626,902,332.44 RMB in Q1 2025, down from 834,169,249.50 RMB in Q1 2024[23] - The cash and cash equivalents at the end of Q1 2025 increased to 702,801,334.96 RMB from 698,284,895.13 RMB at the end of Q1 2024[24] Assets and Liabilities - Total assets increased by 3.16% to CNY 5,878,076,844.70 from CNY 5,698,286,373.15 at the end of the previous year[4] - Total liabilities as of March 31, 2025, were ¥1,914,597,896.85, compared to ¥1,812,422,293.56 at the end of 2024, an increase of 5.67%[15] - The company's total assets reached ¥5,878,076,844.70 as of March 31, 2025, up from ¥5,698,286,373.15 at the end of 2024, an increase of 3.16%[14] - The company's equity attributable to shareholders increased to ¥3,117,551,908.66 as of March 31, 2025, compared to ¥3,057,347,087.18 at the end of 2024, a growth of 1.97%[15] Operational Developments - The company received approval for the raw material drug Fu-Ma-Suan-Fu-Mo-Tuo and the inhalation solution, which is expected to enhance its market presence and performance[10] - The company obtained approval from the Brazilian health authority for the raw material drug Dexamethasone Sodium Phosphate, facilitating market expansion in Brazil[10] - The company received its first production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities[10] - The company passed the FDA cGMP inspection, providing a solid foundation for further international market expansion[10] - The company completed the registration of Naloxone Hydrochloride Injection, enriching its product portfolio[10] - The company is managing a 55.5222% stake in Tianjin Xinda Pharmaceutical Co., Ltd., enhancing its strategic investments[11] Inventory and Receivables - Accounts receivable increased to ¥426,084,165.89 in Q1 2025, compared to ¥291,238,382.36 in Q4 2024, marking a significant rise of 46.2%[13] - Inventory levels were reported at ¥665,055,904.34 as of March 31, 2025, slightly up from ¥651,915,382.71 at the end of 2024, an increase of 2.0%[13] - Short-term borrowings increased to ¥125,711,648.86 in Q1 2025 from ¥108,576,306.93 in Q4 2024, reflecting a rise of 15.5%[14]